Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Immunodiagnostic Systems Hldgs

11 Jun 2021 12:00

RNS Number : 6296B
Peel Hunt LLP
11 June 2021
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Immunodiagnostic Systems Holdings Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Immunodiagnostic Systems Holdings Plc

(d) Date dealing undertaken:

10 June 2021

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Buy

562

377.00 GBx

377.00 GBx

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

11 June 2021

 

Contact name:

Paul Crispin

Telephone number:

0207 418 8988

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERSFFSAFEFSEIM
Date   Source Headline
10th Sep 20147:00 amRNSAcquisition of Dia.Metra S.r.l.
21st Aug 20147:00 amRNSChinese FDA clearance for the IDS-iSYS instrument
4th Aug 20145:59 pmRNSAGM Results
4th Aug 20147:00 amRNSAGM Statement
30th Jul 201410:25 amRNSAdditional Listing
14th Jul 201411:36 amRNS2014 Annual Report & Accounts and Notice of AGM
24th Jun 20147:00 amRNSFinal Results
12th May 201410:51 amRNSHolding(s) in Company
15th Apr 20147:00 amRNSTrading Statement
13th Mar 20144:40 pmRNSSecond Price Monitoring Extn
13th Mar 20144:35 pmRNSPrice Monitoring Extension
7th Mar 20147:00 amRNSDirectorate Change
15th Jan 20144:28 pmRNSHolding(s) in Company
9th Jan 20147:00 amRNSFDA clearance of Direct Renin assay on IDS-iSYS
8th Jan 201412:47 pmRNSAdditional Listing
19th Dec 20134:36 pmRNSAdditional Listing
12th Dec 20136:20 pmRNSHolding(s) in Company
12th Dec 20136:19 pmRNSHolding(s) in Company
27th Nov 20137:00 amRNSHalf Yearly Report
10th Oct 20137:00 amRNSTrading Statement
8th Oct 20134:29 pmRNSHolding(s) in Company
8th Oct 20134:26 pmRNSHolding(s) in Company
27th Sep 201312:40 pmRNSHolding(s) in Company
24th Sep 20131:15 pmRNSAdditional Listing
4th Sep 20137:00 amRNSHolding(s) in Company
28th Aug 201312:46 pmRNSAdditional Listing
31st Jul 201312:20 pmRNSAdditional Listing
29th Jul 20133:24 pmRNSHolding(s) in Company
26th Jul 20133:08 pmRNSResult of AGM
26th Jul 201312:00 pmRNSAGM Statement
2nd Jul 20139:41 amRNSDirector/PDMR Shareholding
28th Jun 20139:46 amRNSAdditional Listing
28th Jun 20139:00 amRNSAnnual Report and AGM
26th Jun 20137:00 amRNSAdditional Listing
24th Jun 20137:00 amRNSFDA clearance of 1,25-Dihydroxy Vitamin D assay
21st Jun 20137:00 amRNSImmunodiagnostic Systems streamlines Board
17th Jun 20137:00 amRNSFinal Results
10th May 20134:29 pmRNSHolding(s) in Company
9th May 20133:22 pmRNSAdditional Listing
2nd May 20137:41 amRNSEntry into Chinese Diagnostics Market
25th Apr 20134:17 pmRNSTrading Update - Replacement
23rd Apr 20139:45 amRNSHolding(s) in Company
16th Apr 20135:03 pmRNSHolding(s) in Company
16th Apr 201311:42 amRNSHolding(s) in Company
10th Apr 20137:00 amRNSDistribution Agreement
10th Apr 20137:00 amRNSTrading Statement
5th Apr 201310:22 amRNSDirector/PDMR Shareholding
4th Apr 20134:43 pmRNSHolding(s) in Company
11th Feb 20137:00 amRNSCollaboration with Diagnostica Stago
14th Dec 20122:28 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.